



Bladder cancer that is unresponsive to intravesical therapies is difficult to treat.  Patients with this disease usually 
have to try salvage therapies, partial cystectomy, or radical cystectomy.  Unfortunately, the population afflicted by 
bladder cancer is older and frailer than those afflicted by other cancers with mortality approaching 1.5% and 
readmission rates approaching 64%.  These patients are left with no other options aside from participating in a 
clinical trial to delay or avoid surgery.  We hypothesized that participation in a clinical trial provides survival 
benefits when controlling for tumor stage and pathology in the case of non-muscle invasive bladder cancer that is 
refractory to intravesical Bacillus Calmette-Guérin (BCG).  Using our Institutional Review Board (IRB) approved 
Columbia Urologic Oncology Database, 55 patients with BCG-refractory NMIBC (29 clinical trial patients, 26 
non-clinical trial patients) were identified between 2008 and 2012. Clinical characteristics, demographics, and 
outcomes were obtained from the medical records.  Non-clinical trial patients had fewer mean BCG instillations 
than their clinical trial counterparts (7.8 versus 11.5 doses, p < .01). Kaplan Meier (KP) curves for Overall Survival 
(OS) and Cancer Specific Survival (CSS) indicate an increased survival benefit for patients enrolled in a clinical 
trial (OS: χ²   = 8.802, p< 0.01, median of 6.68 years versus 3.15 years; CSS: χ²  = 10.205, p < 0.01, mean 5.6 years 
versus 2.65 years).   The data support the notion that there may be an inherent survival benefit gained by virtue of 
being included in a clinical trial.  The drivers of this survival benefit may include more interactions with the 
hospitals and clinics, greater patient involvement in their health care, and increased surveillance by clinicians. 
Introduction 
Among cancers in the United States, bladder cancer is 
the 4th most common cancer in males and the 12th 
most common cancer in females.  There will be 1
around 74,960 new cases overall accompanied by an 
estimated 15,580 deaths for the year 2015. However, 
bladder cancer is highly neglected in terms of funding 
and public attention, which is not concomitant to its 
incidence and burden on society. It is likely to appear 
as the 11th most mentioned cancer in the media 
despite the fact that its actual incidence in the world is 
6th.  Moreover, when people are asked about its 2
perceived incidence, it ranks 15th in comparison to 
other more rare cancers like brain, thyroid, stomach, 
bone/muscle, kidney, pancreatic, and blood/
leukemia.  This has dramatic consequence for funding 3
as bladder cancer receives less funding than other 
cancers relative to its incidence; the National Cancer 
Institute reports state that $23.4 million is spent on 
bladder cancer, while other more rare entities like 
brain cancer have much more funding to the tune of 
171 million.  This lack of awareness and funding 4
makes it very difficult to recruit patients for clinical 
trials and limits the amount of clinical trials available 
to patients. 
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Within bladder cancer, there are two clinical entities 
that are treated separately given their clinical 
management and outcomes. Muscle invasive bladder 
cancer (MIBC) is defined by invasion of the malignant 
cells past the detrusor muscle. For patients with this 
disease, radical cystectomy (RC) and urinary 
d ive rs i on i s w ar r ante d w it h ne o a djuve nt 
chemotherapy in the form of platinum based agents.  5
There is also non-muscle invasive bladder cancer 
(NMIBC), which is defined by malignant cells that are 
on the urothelial lining of the bladder but that do not 
invade into the musuclaris propria of the detrusor 
muscle.  
At diagnosis, usually done by endoscopy with biopsy, 
around 75% of cases are NMIBC; these patients are at 
high risk of recurrence once treated with a 
transurethral urinary resection of the bladder, which 
involves removing the suspicious mass or cauterizing 
any suspicious areas to kill malignant cells.  For this 6
group, bladder-preserving strategies are employed 
after ward. Thes e may involve int raves ica l 
immunotherapy or chemotherapy. In select cases and 
where all else fails, salvage therapies are attempted 
such as partial cystectomy and other intravesical 
treatments. All of these attempt to prolong a patient’s 
time with their natural bladder function and avoid the 
prospect of RC, which is a highly morbid surgery with 
over 64% complication rate in 90 days post-surgery 
and 1.5% mortality rate 30 days post-surgery.  7
However, those patients who undergo salvage 
strategies and refuse RC after failing primary therapies 
are at high risk of recurrence, their risk varying 
according to their tumor stage, high or low grade, 
and/or presence of carcinoma-in-situ with other 
histological tumor subtype.  8
Existing options for these patients at high risk of 
recurrence and/or progression include the gold line 
intravesical treatment for bladder cancer, which is 
Bacillus Calmette-Guérin (BCG). This treatment is 
specifically for high-risk tumors defined as high-grade 
Ta, T1, and Tis, as it reduces disease recurrence while 
re m ai n i ng sup e r i or to ot h e r i nt r ave s i c a l 
chemotherapeutic agents like adriamycin, mitomycin 
C, or epirubicin.  Moreover, in this high risk group, a 9
meta-analysis of mitomycin C showed that patients 
receiving a single dose within 24 hours of a 
transurethral resection of the tumor have up to 39% 
lower r isk of recurrence, independent of 
chemotherapeutic agent received afterward.  10
Bacillus Calmette Guerin (BCG) – refractory NMIBC 
is a disease in a subset of patients defined as either 
failing to respond to BCG, recurring after being 
cancer free, intolerant to BCG due to side effects, or 
not receiving adequate amounts of BCG instillations. 
This population has worse outcomes than those who 
permanently respond to BCG, and those who are at 
high risk usually are recommended to undergo 
neoadjuvant platinum-based chemotherapy followed 
by radical cystectomy.8 The salvage intravesical 
therapies available to these patients yield variable and 
inconsistent response results with rates of remission in 
19-21% of the time using mitomycin C, valrubicin, 
docetaxel, and paclitaxel.  At this point, after these 11
salvage therapies, patients are considered multi-drug 
resistant and again are recommended to undergo 
radical cystectomy; alternatively, a partial cystectomy 
may be attempted. However, in both cases of BCG 
refractory disease and MDR NMIBC bladder cancer, 
these patients are either not good surgical candidates 
or decline to have a radical cystectomy. This is the 
population for whom clinical trials may offer a 
glimmer of hope for patients to retain their bladder. 
However, one must balance the risk of delaying 
curative surgery with the possibility of a cure that a 
clinical trial can provide to patients who may not 
survive the surgery. 
At the J. Bentley Squier Urologic Clinic at Columbia-
Presbyterian Medical Center, our department has 
enrolled patients across various studies at in phase I 
and phase II trials for agents like intravesical albumin-
bound docetaxal, intravesical albumin-bound 
sirolimus, intravesical cisplatin, gemcitabine, 
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cabazitaxel, oral mTOR inhibitor with intravesical 
gemcitabine, adenovirus carrying GM-CSF coding 
gene aiming for stimulation of interferon production, 
and other medications aimed at trying to help this 
population of patients who do not have other options 
besides surgery. Nevertheless, a clinical concern for 
this special population is that many of them forgo the 
decision of having surgery with the hope of preserving 
their bladder but compromising their outcomes. Some 
of these patients may theoretically have progression 
while receiving experimental treatments. Hence, we 
wanted to know whether clinical trial participation 
affords any survival advantages or disadvantages in 
comparison to patients who do not enroll in a clinical 
trial. Moreover, we wanted to investigate the clinical 
and demographical characteristics of patients who 
enroll in clinical trials at Columbia to find ways to 
optimize clinical trial enrollment. 
Materials and Methods 
The Institutional Review Board (IRB) Columbia 
Urologic Oncology Database was queried for patients 
who participated in a clinical trial at Columbia from 
2008 to 2012 for a total of 77 patients. A second query 
was done for all patients refractory to BCG and who 
were given the choice of receiving salvage intravesical 
treatment (interferon and BCG, paclitaxel, or 
docetaxel), radical cystectomy, or enrolling in a 
clinical trial for a total of 158 patients. We included 
only patients who had a visible tumor T1 high grade 
or higher and with or without carcinoma in situ in 
order to control for stage, grade, and baseline risk. We 
also excluded those with only carcinoma in situ, as 
they represent a higher risk population. This led to a 
total of 29 clinical trial patients and 26 non-clinical 
trial patients who had all of their care at Columbia 
and matched for disease severity. Demographic 
variables recorded through chart review included age, 
sex, marital status, religion, race, ethnicity, health 
insurance, driving distance, public transportation 
time, education, urban/rural neighborhood, and zip 
code. Incomes and driving distances were estimated 
using the United Census 
Bureau zip code income look 
u p a n d G o o g l e Map s , 
respectively. Other clinical 
variables recorded via chart 
review included time to 
r e c u r r e n c e f r o m l a s t 
i nt r ave s i c a l t re at me nt , 
Charlson Comorbidity Index 
(CCI) adjusted for age, 
pathological and histological 
characteristics of recurrence, 
type of BCG failure, number 
of BCG instillations, and 
rates of radica l/par t ia l 
c y s t e c t o m y ( R C / P C ) 
between the groups.  
A Chi-square or Fisher’s 
Exact Test was performed for categorical variables. A 
Mann Whitney Test was performed for non-
parametric data and comparisons. A Student T-test 
was performed for analysis and comparisons of 
continuous variables. Kaplan Meier (KM) methods 
were used to compare overall survival (OS), cancer 
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specific survival (CSS), and disease free survival 
(DFS). 
Results 
Increased education (Fisher’s Exact Test, p < 0.013), 
rural-suburban living (Fisher’s Exact Test, p <0.011), 
and increased distance from our institution (52.85 
miles versus 23 miles, Mann Whitney U-test, p < 0.01) 
were associated with enrollment in a clinical trial 
compared with patients who did not enroll. With 
regards to other demographics, there were no 
associations between clinical trial participation and 
mean yearly incomes, age of recurrence, sex, religion, 
marital status, number of children, transportation 
time, smoking history, or insurance status 
(Supplementary Table 1). 
With regards to clinical characteristics, there were no 
differences in CCI at diagnosis, pathology at 
recurrence, BCG failure type, or RC/PC rates between 
the two groups (Supplementary Table 2). There were 
no differences in median age at bladder cancer 
recurrence. However, clinical trial patients received 
more BCG instillations in their lifetime than their 
non-clinical trial counterparts (11.85 versus 7.83 
doses, Student T-test, p < .0007). KM curves for OS 
and CSS indicate an increased survival benefit for 
patients enrolled in a clinical trial (OS: χ² = 8.802, p< 
0.01, median of 6 .68 years versus 3.15 years; CSS: χ² = 
10.205, p < 0.01, mean 5.6 years versus 2.65 years, 
Figures 1, 2). These survival benefits were seen despite 
the fact that DFS were not different between groups 
(χ² = 1.569, p=0.210, 3.57 years for clinical trial 
patients versus 1.22 years for non-clinical trial 
patients, Figure 3). 
Discussion 
This retrospective study looked at whether a clinical 
trial affords clinical benefits for patients who decide to 
participate in these trials. We looked at both overall 
survival and cancer specific survival. We showed that 
patients in a clinical trial might have a survival 
advantage compared with those who do not 
participate in a clinical trial, with a median survival of 
two times higher than non-clinical trial patients with 
similar disease stages. Moreover, with regards to 
demographic analysis of the cohorts, patients on a 
clinical trial were more educated, lived in rural/
suburban areas, and lived at an increased distance 
from our institution. This may suggest that patients 
who are recruited to enroll are an educated, motivated 
group that seeks inclusion into a clinical trial. The 
clinical trial information is available in the public 
domain via the National Cancer Institute website and 
other sources. However, this finding also suggests a 
possible selection bias in the Phase I and II clinical 
trials held at our institution for NMIBC, as we may 
unknowingly choose a more educated patient 
population for enrollment. 
With regards to clinical characteristics, patients that 
enroll in clinical trials do not differ significantly from 
those who do not with regards to their comorbidities 
as assessed by the comparison of their CCI. This was 
unexpected given that usually these trials tend to 
include patients who are not surgical candidates. 
Moreover, of interest was the fact that patients who 
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Figure 1. Kaplan-Meier curve plotting overall survival 
since initial pathological recurrence in days with 
patients censored at death (χ² = 8.802, p< 0.01, median 
of 6 .68 years versus 3.15 years).
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did enroll in a clinical trial were a much higher risk 
subgroup of BCG refractory disease than the non-
clinical trial group. Previous research at our 
institution has shown that increasing amounts of 
intravesical therapies including BCG instillations 
prior to radical cystectomy leads to worse outcomes 
and decreased survival after surgery.  Hence, the 12
clinical trial patients appear to be a much higher risk 
group, yet this group still maintains an overall survival 
benefit in comparison to the non-clinical trial 
patients. 
This is an unexpected result and should be interpreted 
cautiously. There are many instances of patients who 
are wary of enrolling in clinical trials given the delay 
to ultimate curative treatment for those who do have 
the option. In other cases, the providers sometimes 
weigh the benefits of a clinical trial for patients who 
may benefit from immediate radical cystectomy. 
Although these results may offer some relief to 
providers, they need to be tempered with existing 
studies indicating that longer wait times for surgery 
predict worse outcomes.  13
In the literature, a similar analysis has been done with 
a large Cancer Registry with stage I to IV solid organ 
tumors, where enrollment into clinical trials predicted 
lower overall and cancer-specific mortality among 
cancer sites.  However, on multivariate analysis, only 14
lung, colon, and breast cancers were statistically 
significant, indicating that patients enrolling in a 
clinical trial tend to have more favorable and lower 
risk characteristics than the broader population of 
patients with the given disease. This paper neither 
included the urological cancers nor looked at the 
individual risk factors of the patients for a given 
disease as we have done with our analysis of patients 
enrolled in a clinical trial for BCG refractory bladder 
cancer. 
Some reasons why clinical trial enrollment itself may 
afford survival benefits include more consistent 
clinical follow up, more interventions and surveillance 
by the medical team, and increased engagement of 
patients with their health. Nevertheless, this reason 
may be confounded by the fact that patients who 
enroll in clinical trials tend to be more educated and 
live in areas that are associated with high 
socioeconomic status enclaves in suburban 
communities.  Contrary to other studies, there were 15
no differences in insurance status or income among 
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Figure 2. Kaplan-Meier curve plotting cancer 
specific survival since initial pathological 
recurrence in days with patients censored at death 
due to bladder cancer (χ² = 10.205, p < 0.01, mean 
5.6 years versus 2.65 years).
Figure 3. Kaplan-Meier curves plotting patients that 
after the clinical trial or other treatments undergo 
disease free period and censored for when they have 
subsequent recurrence or death (χ² = 1.569, p=0.210, 
3.57 yrs for clinical trial patients vs 1.22 yrs for non-
clinical trial patients).
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the groups; nevertheless, it is possible that the study 
was underpowered to detect those differences. 
Moreover, underinsured and uninsured status has also 
been implicated in under-enrollment in clinical trials, 
although the best study investigating this relationship 
showed results that were trending toward significance 
but did not meet the threshold.  We did not find any 16
association between insurance status and clinical trial 
enrollment. 
Of greatest concern in our study is the potential for 
selection biases seen in Phase I and Phase 2 trials that 
have taken place in our institution during the time of 
the retrospective study. Although, patient selection is 
a less important factor in these cases given that first 
toxicity and then efficacy tend to be the endpoints 
analyzed, this does lead to questions about how well 
we are recruiting patients and how well we will be able 
to do so in the future. The data we have so far suggest 
that we have to increase the emphasis on recruiting 
patients who may not have a college degree or 
graduate degree, actively improve enrollment people 
within the community of Washington Heights, 
increase the number of minorities enrolled including 
Hispanics and African Americans, and increase 
outreach to segments of the population with less 
access to information on clinical trials. All of these 
actions may help overcome this potential bias. This is 
especially important for bladder cancer as incidence 
will only increase in the future in the contexts of an 
ever- expanding minority population and a more 
chronically ill, aging population.  17
Our study has several limitations. First, patients were 
matched by disease severity but not for other variables 
given the low case numbers. The patients selected as a 
group for comparison were patients who were similar 
in terms of disease burden (no Tis on pathology and 
clinically met criteria for enrolling in any trial dealing 
with BCG refractory) and for whom we had enough 
follow up to longitudinally track across our database. 
This may have created a lead-time bias, as we selected 
patients who may have survived instead of recruiting a 
representative group across all risk groups. Moreover, 
we excluded those who had low-grade disease and 
those who had only carcinoma in situ on pathology. 
The latter cases were excluded from analysis because 
they represented a unique population for whom 
endoscopic surveillance and biopsy tends to be 
unreliable, making progression or recurrence harder 
to measure in comparison with those who have a 
tumor and visible growth at recurrence. However, we 
did include those who have mixed Tis and visible 
tumors in our retrospective analysis. 
Moreover, we could not assess all pathological and 
demographic data for patients who received their 
diagnosis or long-term follow up outside of our 
institution. In addition, everyone referred to 
Columbia in the clinical trial group was from an 
outside clinic. Hence, it was hard to collect reliable 
information regarding the total number of BCG 
instillations and the exact point at which patients 
failed or the type of BCG failure experienced. 
Furthermore, many of the trials that were recruiting at 
the time enrolled patients who had a specific high 
functional status, and each clinical trial had different 
follow-ups and protocols. Hence, these protocols 
might have created a selection bias for patients who 
overall were less frail than those not enrolled in a 
clinical trial. However, there were no differences in 
CCI or age between the groups, indicating that frailty 
was not a difference between the populations. 
Conclusion 
Clinical trials are important for the advancement of 
medicine and treating diseases like BCG refractory 
bladder cancer for which we have few treatments or 
for which the consequences of said treatments are too 
risky to implement. We show here that our patients 
benefitted from clinical trial enrollment in terms of 
cancer specific survival and overall survival but did 
not differ with regards to time to disease recurrence. 
Nevertheless, caution must be exerted as these 
findings may not be applicable to other institutions, 
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and they need to be investigated with more patients over a much longer time span across the country. 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